A detailed history of Verition Fund Management LLC transactions in Gh Research PLC stock. As of the latest transaction made, Verition Fund Management LLC holds 1,140,632 shares of GHRS stock, worth $10.3 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
1,140,632
Previous 1,129,304 1.0%
Holding current value
$10.3 Million
Previous $12 Million 10.48%
% of portfolio
0.08%
Previous 0.09%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$10.5 - $14.81 $118,944 - $167,767
11,328 Added 1.0%
1,140,632 $13.3 Million
Q1 2024

May 14, 2024

SELL
$5.34 - $11.09 $177,186 - $367,977
-33,181 Reduced 2.85%
1,129,304 $12 Million
Q4 2023

Feb 14, 2024

SELL
$5.26 - $11.04 $119,680 - $251,193
-22,753 Reduced 1.92%
1,162,485 $6.74 Million
Q3 2023

Nov 14, 2023

BUY
$9.8 - $14.15 $3.81 Million - $5.51 Million
389,066 Added 48.87%
1,185,238 $11.9 Million
Q2 2023

Aug 14, 2023

SELL
$7.88 - $12.74 $1.14 Million - $1.84 Million
-144,501 Reduced 15.36%
796,172 $9.45 Million
Q1 2023

May 15, 2023

BUY
$6.02 - $10.92 $257,734 - $467,517
42,813 Added 4.77%
940,673 $7.52 Million
Q4 2022

Feb 14, 2023

BUY
$9.2 - $13.5 $2.67 Million - $3.91 Million
289,736 Added 47.64%
897,860 $8.73 Million
Q2 2022

Aug 15, 2022

SELL
$8.99 - $19.87 $3.91 Million - $8.64 Million
-434,975 Reduced 41.7%
608,124 $6.07 Million
Q4 2021

Feb 14, 2022

SELL
$14.1 - $27.9 $3.1 Million - $6.14 Million
-220,025 Reduced 17.42%
1,043,099 $24.3 Million
Q3 2021

Nov 15, 2021

SELL
$16.51 - $23.68 $1.24 Million - $1.78 Million
-75,000 Reduced 5.6%
1,263,124 $27.9 Million
Q2 2021

Aug 16, 2021

BUY
$19.25 - $21.73 $25.8 Million - $29.1 Million
1,338,124 New
1,338,124 $29.1 Million

Others Institutions Holding GHRS

About GH Research PLC


  • Ticker GHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,020,800
  • Market Cap $470M
  • Description
  • GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...
More about GHRS
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.